Spots Global Cancer Trial Database for tanespimycin
Every month we try and update this database with for tanespimycin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00019708 | Extranodal Marg... Nodal Marginal ... Non-Hodgkin Lym... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Splenic Margina... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... | tanespimycin | 19 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer | NCT00577889 | Adenocarcinoma ... Recurrent Pancr... Stage IV Pancre... | gemcitabine hyd... tanespimycin | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer | NCT00093496 | Primary Periton... Recurrent Ovari... Stage III Ovari... Stage IV Ovaria... | gemcitabine hyd... tanespimycin | 18 Years - | National Cancer Institute (NCI) | |
| Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors | NCT00047047 | Unspecified Adu... | gemcitabine hyd... tanespimycin cisplatin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate | NCT00100997 | Leukemia | tanespimycin | 18 Years - | National Cancer Institute (NCI) | |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis | NCT00132015 | Chronic Myelopr... Leukemia Lymphoma Nonneoplastic C... Precancerous Co... | tanespimycin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors | NCT00058253 | Recurrent Prost... Stage IV Prosta... Unspecified Adu... | tanespimycin docetaxel | 18 Years - | National Cancer Institute (NCI) | |
| 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma | NCT00117988 | Anaplastic Larg... Recurrent Adult... Recurrent Mantl... | tanespimycin | 16 Years - | National Cancer Institute (NCI) | |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer | NCT00093405 | Kidney Cancer | tanespimycin | 18 Years - | National Cancer Institute (NCI) | |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma | NCT00104897 | Melanoma (Skin) | tanespimycin | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse | NCT00546780 | Multiple Myelom... | Tanespimycin Bortezomib | 18 Years - | Bristol-Myers Squibb | |
| 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy | NCT00118092 | Adenocarcinoma ... Recurrent Prost... Stage IV Prosta... | tanespimycin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma | NCT00104897 | Melanoma (Skin) | tanespimycin | 18 Years - | National Cancer Institute (NCI) | |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | NCT00079404 | Acute Undiffere... Recurrent Child... Recurrent Child... Secondary Acute... Unspecified Chi... | tanespimycin | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer | NCT00577889 | Adenocarcinoma ... Recurrent Pancr... Stage IV Pancre... | gemcitabine hyd... tanespimycin | 18 Years - | National Cancer Institute (NCI) | |
| Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia | NCT00066326 | Leukemia | imatinib mesyla... tanespimycin | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00019708 | Extranodal Marg... Nodal Marginal ... Non-Hodgkin Lym... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Splenic Margina... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... | tanespimycin | 19 Years - | National Cancer Institute (NCI) | |
| Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer | NCT00118248 | Recurrent Thyro... Stage IV Follic... Stage IV Papill... Thyroid Gland M... | tanespimycin | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer | NCT00093496 | Primary Periton... Recurrent Ovari... Stage III Ovari... Stage IV Ovaria... | gemcitabine hyd... tanespimycin | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma | NCT00514371 | Multiple Myelom... | tanespimycin Bortezomib | 18 Years - | Bristol-Myers Squibb | |
| 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor | NCT00087217 | Unspecified Adu... | tanespimycin paclitaxel laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer | NCT00118248 | Recurrent Thyro... Stage IV Follic... Stage IV Papill... Thyroid Gland M... | tanespimycin | 18 Years - | National Cancer Institute (NCI) | |
| 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | NCT00098488 | B-cell Chronic ... Prolymphocytic ... Refractory Chro... | tanespimycin rituximab | 18 Years - | National Cancer Institute (NCI) | |
| 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors | NCT00121264 | Unspecified Adu... | sorafenib tosyl... tanespimycin laboratory biom... pharmacological... magnetic resona... | 18 Years - | National Cancer Institute (NCI) | |
| 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors | NCT00121264 | Unspecified Adu... | sorafenib tosyl... tanespimycin laboratory biom... pharmacological... magnetic resona... | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer | NCT00004065 | Bladder Cancer Breast Cancer Colorectal Canc... Gastric Cancer Head and Neck C... Kidney Cancer Leukemia Lung Cancer Melanoma (Skin) Ovarian Cancer Prostate Cancer Unspecified Adu... | tanespimycin | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors | NCT00119236 | Unspecified Adu... | tanespimycin irinotecan hydr... | 18 Years - | National Cancer Institute (NCI) | |
| 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors | NCT00119236 | Unspecified Adu... | tanespimycin irinotecan hydr... | 18 Years - | National Cancer Institute (NCI) | |
| Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer | NCT00096109 | Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | tanespimycin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes | NCT00098423 | Accelerated Pha... Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo... | tanespimycin cytarabine | 18 Years - | National Cancer Institute (NCI) | |
| Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin | NCT00779428 | Advanced Malign... | Tanespimycin | 18 Years - | Bristol-Myers Squibb | |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | NCT00079404 | Acute Undiffere... Recurrent Child... Recurrent Child... Secondary Acute... Unspecified Chi... | tanespimycin | 1 Year - 21 Years | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
